Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment

Wang, Kunpeng; Miao, Xiangshui; Kong, Fanyun; Huang, Siqi; Mo, Jinggang; Jin, Chong; Zheng, Yuanna

doi:10.2147/dddt.s323360

Cited by 16 publications

(9 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Gene pathway analysis : The DAVID (the Database for Annotation, Visualization, and Integrated Discovery) database (http://david) is an online, freely available bioinformatics database for differential gene functional and pathway enrichment analysis. [ 22 ]…”

Section: Methodsmentioning

confidence: 99%

“…abcc.ncifcrf.gov/) is an online, freely available bioinformatics database for differential gene functional and pathway enrichment analysis. [22] The obtained potential targets, entered into DAVID, are analyzed online using the Gene Ontology functional annotations (GO) in which the potential targets are involved and the signaling pathways (KEGG) in which they are involved. [23] The results were visualized by plotting the results of the analysis into bubble maps [24] through the mic share database.…”

Section: Network Pharmacology Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease

Pei

Zeng

Chen

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

Objective The key molecular mechanism of palmatine in the treatment of Alzheimer's disease (AD) was investigated in this article. Methods Network pharmacology techniques constructed drug‐target‐disease relationship networks and predictive pathways of action. At the cellular level, lipopolysaccharide (LPS) was used to induce Raw 264.7 cells to establish an inflammation model, and interleukin (IL)‐1β, IL‐6, and tumor necrosis factor (TNF)‐α indicators were examined. Apoptosis was detected using Hoechst 33258. At the animal level, LPS was used to induce AD animal model, and behavioral performance were examined by water maze, and serum biochemical indexes were measured by ELISA. And the expression of PI3K and P‐AKT was observed by immunohistochemistry. Finally, molecular level validation was performed using the molecular docking technique. Results The result of Network pharmacological was predicted that palmatine may treat AD mainly through the PI3K pathway. Palmatine has no significant effect on Raw264.7 cells viability within 0.05 mg/ml, Palmatine can significantly induce Raw264.7 cells to secret IL‐6 and IL1‐β in a concentration‐dependent manner, but it has not obvious impact on NO and TNF‐α. Palmatine has a significant restorative effect on the cell viability of Raw264.7 in a concentration of 0.1 mg/ml. Palmatine can be concentration‐dependent to downregulate the secretion of LPS‐induced IL‐6. At the same time, Palmatine also has a significant effect on the level of TNF‐α induced by LPS, it also can slightly downregulate the secretion of IL‐1β. The results of Hoechst33258 showed that cells in the 0.025 mg/ml and 0.5 mg/ml delivery groups increased with different degrees of bright blue fluorescence, and apoptosis rate decreased. Animal experiments showed that palmatine effectively improved the learning and memory ability of AD mice. The immunohistochemical results exhibited that the expression of PI3K and P‐AKT in the model group decreased, but they were obvious reversed by palmatine The molecular docking results showed that palmatine and key targets had good docking, among which the binding to ERBB2, CDC42, MDM2, and mTOR was the most likely. Conclusion Palmatine has neuroprotective effects. Palmatine could effectively ameliorate memory impairment in AD mice by promoting the PI3K‐AKT pathway. Molecular docking results showed that palmatine has a better binding ability with mTOR.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Network Pharmacology Studiesmentioning

confidence: 99%

Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease

Pei

Zeng

Chen

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

show abstract

“…Network pharmacology, a novel comprehensive analysis tool based on large databases, can help researchers reveal the therapeutic mechanisms of TCM compounds by predicting the potential relationships between drugs, targets, and diseases ( 19 ). The purpose of this study was to detect the chemical components of HMMCR by liquid chromatography electrospray ionization tandem mass spectrometric (LC-ESI-MS/MS), predict the intervention pathways of HMMCR for NSCLC through network pharmacology, and further verify the underlying molecular mechanism through in vitro experiments.…”

Section: Introductionmentioning

confidence: 99%

Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer

Zhang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundHedysarum Multijugum Maxim–Curcumae Rhizoma (HMMCR), a well-known herb pair in traditional Chinese medicine (TCM), has been widely used for the treatment of various cancers. However, the active components of HMMCR and the underlying mechanism of HMMCR for non-small-cell lung carcinoma (NSCLC) remain unclear.MethodsActive ingredients of HMMCR were detected by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS). On this basis, potential targets of HMMCR were obtained from SwissTargetPrediction database. NSCLC-related targets were collected from four public databases (GeneCards, OMIM, TTD, and PharmGkb). The drug ingredients–disease targets network was visualized. The hub targets between HMMCR and NSCLC were further analyzed by protein–protein interaction (PPI), Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Subsequently, the results predicted by network pharmacology were further validated via in vitro experiments.ResultsA total of 181 compounds were identified from the aqueous extract of HMMCR. Through network analysis, a compound–target network including 153 active ingredients of HMMCR and 756 HMMCR-NSCLC co-targets was conducted; 6 crucial compounds and 62 hub targets were further identified. The results of KEGG enrichment analysis showed that PI3K/Akt signaling pathway may be the critical pathway of HMMCR in the treatment of NSCLC. The in vitro experiments indicated that HMMCR inhibits the proliferation and migration of NSCLC cells via inactivation of the PI3K/Akt signaling pathway, consistent with the results predicted by network pharmacology.ConclusionIntegrating LC-ESI-MS/MS, network pharmacology approach, and in vitro experiments, this study shows that HMMCR has vital therapeutic effect on NSCLC through multi-compound, multi-target, and multi-pathway, which provides a rationale for using HMMCR for the treatment of NSCLC.

show abstract

“…Currently, surgical resection remains the only option to cure pancreatic cancer. However, adjuvant chemotherapy has made significant progress in improving the prognosis of patients with pancreatic cancer ( Wang et al, 2021a ). Adjuvant chemotherapy regimens include FOLFIRINOX [5-fluorouracil (FU), folate, irinotecan and oxaliplatin (OX)] and gemcitabine combined with sodium protein, sodium and paclitaxel and have been shown to prolong overall survival ( Mizrahi et al, 2020 ).…”

Section: Introductionmentioning

confidence: 99%

Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours

et al. 2022

View full text Add to dashboard Cite

Digestive system tumours, including stomach, colon, esophagus, liver and pancreatic tumours, are serious diseases affecting human health. Although surgical treatment and postoperative chemoradiotherapy effectively improve patient survival, current diagnostic and therapeutic strategies for digestive system tumours lack sensitivity and specificity. Moreover, the tumour’s tolerance to drug therapy is enhanced owing to tumour cell heterogeneity. Thus, primary or acquired treatment resistance is currently the main hindrance to chemotherapy efficiency. N6-methyladenosine (m6A) has various biological functions in RNA modification. m6A modification, a key regulator of transcription expression, regulates RNA metabolism and biological processes through the interaction of m6A methyltransferase (“writers”) and demethylase (“erasers”) with the binding protein decoding m6A methylation (“readers”). Additionally, m6A modification regulates the occurrence and development of tumours and is a potential driving factor of tumour drug resistance. This review systematically summarises the regulatory mechanisms of m6A modification in the drug therapy of digestive system malignancies. Furthermore, it clarifies the related mechanisms and therapeutic prospects of m6A modification in the resistence of digestive system malignancies to drug therapy.

show abstract

Integrating Network Pharmacology and Experimental Verification to Explore the Mechanism of Effect of Zuojin Pills in Pancreatic Cancer Treatment

Cited by 16 publications

References 49 publications

Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease

Network pharmacology and molecular docking integrated strategy to investigate the pharmacological mechanism of palmatine in Alzheimer's disease

Integrated Network Pharmacology and Experimental Verification to Explore the Molecular Mechanism of Hedysarum Multijugum Maxim–Curcumae Rhizoma Herb Pair for Treating Non-Small Cell Lung Cancer

Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of Digestive System Tumours

Contact Info

Product

Resources

About